BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16315649)

  • 1. Maximum information designs.
    Lachin JM
    Clin Trials; 2005; 2(5):453-64. PubMed ID: 16315649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and analysis of group sequential logrank tests in maximum duration versus information trials.
    Kim K; Boucher H; Tsiatis AA
    Biometrics; 1995 Sep; 51(3):988-1000. PubMed ID: 7548714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On sample size estimation and re-estimation adjusting for variability in confirmatory trials.
    Wu PS; Lin M; Chow SC
    J Biopharm Stat; 2016; 26(1):44-54. PubMed ID: 26378970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of group sequential logrank tests in a maximum duration trial.
    Lan KK; Lachin JM
    Biometrics; 1990 Sep; 46(3):759-70. PubMed ID: 2242413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blinded and unblinded internal pilot study designs for clinical trials with count data.
    Schneider S; Schmidli H; Friede T
    Biom J; 2013 Jul; 55(4):617-33. PubMed ID: 23703749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exact sample sizes needed to detect dependence in 2 x 3 tables.
    Sánchez MS; Basten CJ; Ferrenberg AM; Asmussen MA; Arnold J
    Theor Popul Biol; 2006 Mar; 69(2):111-20. PubMed ID: 16343573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the adaptive performance of flexible sample size designs with treatment difference in an interval.
    Liu GF; Zhu GR; Cui L
    Stat Med; 2008 Feb; 27(4):584-96. PubMed ID: 17634972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size re-estimation in group-sequential response-adaptive clinical trials.
    Morgan CC
    Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient group sequential designs when there are several effect sizes under consideration.
    Jennison C; Turnbull BW
    Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the efficiency of adaptive sample size design.
    Cui L; Zhang L
    Stat Med; 2019 Mar; 38(6):933-944. PubMed ID: 30450621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance, Errors, Power, and Sample Size: The Blocking and Tackling of Statistics.
    Mascha EJ; Vetter TR
    Anesth Analg; 2018 Feb; 126(2):691-698. PubMed ID: 29346210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size for two-stage studies with maintenance therapy.
    Feng W; Wahed AS
    Stat Med; 2009 Jul; 28(15):2028-41. PubMed ID: 19382105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size adaptation in fixed-dose combination drug trial.
    James Hung HM; Wang SJ
    J Biopharm Stat; 2012; 22(4):679-86. PubMed ID: 22651108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient adaptive designs with mid-course sample size adjustment in clinical trials.
    Bartroff J; Lai TL
    Stat Med; 2008 May; 27(10):1593-611. PubMed ID: 18275090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical power and estimation of the number of required subjects for a study based on the t-test: a surgeon's primer.
    Livingston EH; Cassidy L
    J Surg Res; 2005 Jun; 126(2):149-59. PubMed ID: 15919413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On efficient two-stage adaptive designs for clinical trials with sample size adjustment.
    Liu Q; Li G; Anderson KM; Lim P
    J Biopharm Stat; 2012; 22(4):617-40. PubMed ID: 22651105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Test equality and sample size calculation based on risk difference in a randomized clinical trial with noncompliance and missing outcomes.
    Lui KJ; Chang KC
    Biom J; 2008 Apr; 50(2):224-36. PubMed ID: 18264992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blinded sample size recalculation in clinical trials with binary composite endpoints.
    Sander A; Rauch G; Kieser M
    J Biopharm Stat; 2017; 27(4):705-715. PubMed ID: 27295402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A ratio test in active control non-inferiority trials with a time-to-event endpoint.
    Wang YC; Chen G; Chi GY
    J Biopharm Stat; 2006; 16(2):151-64. PubMed ID: 16584064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.